Om

Medicus Pharma Ltd. is a biotech and life sciences company focused on advancing precision-guided therapeutic assets through clinical development programs. The company’s current portfolio centers on novel treatments in dermatology and oncology, including SkinJect, a localized immuno-oncology product being developed for non-melanoma skin diseases such as basal cell carcinoma and Gorlin syndrome. It is also developing Teverelix, a next-generation GnRH antagonist being studied for prostate cancer, acute urinary retention related to enlarged prostate, and endometriosis. Medicus Pharma Ltd. works as a clinical-stage developer, supporting research, trial activity, and regulatory progress for specialized drug candidates aimed at difficult-to-treat conditions. Headquartered in Canada with operations in the United States, the company plays a focused role in the life sciences market by advancing targeted therapies from development through clinical evaluation.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I MEDICUS PHARMA MED ENDAVU: Køb Medicus Pharma ($MDCX) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Medicus Pharma, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.